Recurrent and/or metastatic squamous cell carcinoma of the head and neck (HNSCC)
continues to be a source of significant morbidity and mortality worldwide. Agents that target …

Patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
(SCCHN) have a poor prognosis, particularly those whose disease has progressed on …

Squamous cell carcinoma of the head and neck (HNSCC) while curable in many cases with
surgery, radiation, and chemotherapy, remains a disease that is associated with significant …

BACKGROUND. The epidermal growth factor receptor (EGFR) inhibitor cetuximab is active
in recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). The …

Introduction: The standard of care for patients with locally-advanced head and neck cancer
is chemoradiation or surgical resection followed by radiation treatment with or without …

EGFR belongs to the ErbB family of receptor tyrosine kinases and is associated with worse
prognosis in head and neck squamous cell carcinoma (HNSCC). Cetuximab is a …

Cetuximab remains to date the only targeted therapy approved for the treatment of head and
neck squamous cell carcinoma (HNSCC). The EGFR pathway plays a key role in the …

Approaches to the treatment of locally advanced and recurrent and/or metastatic squamous
cell carcinoma of the head and neck (SCCHN) have been limited by their toxicity. Effective …

Cetuximab (Erbitux®) is a chimeric monoclonal antibody directed against the human
epidermal growth factor receptor (EGFR). EGFR is overexpressed and/or upregulated in …

Expression of EGF receptor (EGFR) is frequently elevated in squamous cell carcinoma of the
head and neck (SCCHN). Cetuximab is an anti-EGFR monoclonal antibody that has been …